Gossamer Bio reports 90.5% participation in convertible note exchange

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/24/2026

1. DECK
2. RNG
3. WDC
4. BYD
5. WCN
6. SPOT
7. BMY
8. SPY
9. FIX
10. TSCO

Go back to Gossamer Bio reports 90.5% participation in convertible note exchange

Gossamer Bio, Inc. Announces Early Tender Results and Early Settlement for Exchange Offer and Consent Solicitation with Respect to Existing Convertible Notes

June 3, 2026 8:00 AM EDT

SAN DIEGO--(BUSINESS WIRE)-- Gossamer Bio, Inc. (NASDAQ: GOSS) (the Company or Gossamer), a biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced the early tender results of its previously announced exchange offer (the Exchange Offer) to exchange any and all of its 5.00% Convertible Senior Notes due 2027 (the Existing Convertible Notes) for a pro rata portion of (i) up to $72.0 million in aggregate principal amount of its new 7.50% Convertible Senior Secured First Lien Notes due 2030 (the New... More